These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 8281716

  • 1. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG, Fischer ER, Harris DC.
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [Abstract] [Full Text] [Related]

  • 2. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 3. Erythropoietin response and route of administration.
    Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK.
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [Abstract] [Full Text] [Related]

  • 4. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C, Blumberg A.
    Schweiz Med Wochenschr; 1990 Feb 17; 120(7):217-20. PubMed ID: 2309110
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD.
    Icardi A, Paoletti E, Molinelli G.
    Adv Perit Dial; 1990 Feb 17; 6():292-5. PubMed ID: 1982830
    [Abstract] [Full Text] [Related]

  • 11. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ, Kent AB, Becker GJ, McMahon LP.
    Nephrology (Carlton); 2004 Jun 17; 9(3):153-60. PubMed ID: 15189176
    [Abstract] [Full Text] [Related]

  • 12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Jun 17; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin].
    Boratyńska M, Mazanowska O, Szewczyk Z.
    Pol Merkur Lekarski; 1996 Nov 17; 1(5):329-31. PubMed ID: 9273209
    [Abstract] [Full Text] [Related]

  • 14. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B, Polito-Bouloux C, Rivory JP, Donnadieu P, Taib J, Florence P, Mion C.
    Nephrologie; 1990 Nov 17; 11(1):5-10. PubMed ID: 2374643
    [Abstract] [Full Text] [Related]

  • 15. [Effectiveness of and tolerance to human recombinant erythropoietin in the treatment of kidney failure anemia in children undergoing continuous peritoneal dialysis. Multicenter study].
    Parchoux B, Broyer M, Cochat P, Burguet A, Menget A, Benoît D, Nivet H, Fischbach M, Geisert J, Dabout D.
    Pediatrie; 1993 Nov 17; 48(5):397-401. PubMed ID: 7777395
    [Abstract] [Full Text] [Related]

  • 16. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May 17; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
    Durmaz O, Demirkaya M, Sevinir B.
    Pediatr Hematol Oncol; 2011 Sep 17; 28(6):461-8. PubMed ID: 21707225
    [Abstract] [Full Text] [Related]

  • 19. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC, Temple RM, Kwan JT.
    Nephrol Dial Transplant; 2007 Mar 17; 22(3):784-93. PubMed ID: 16968726
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN, Chaidos A, Gouva M, Christou L, Panteli K, Kapsali E, Bourantas KL.
    J Exp Clin Cancer Res; 2004 Mar 17; 23(1):47-52. PubMed ID: 15149150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.